The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:2269-2271 December 4, 2003 Number 23
NextNext

Antimyelin Antibodies in Multiple Sclerosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Antel, J. P.
-Related Article
by Berger, T.
-PubMed Citation
To the Editor: In their article on the use of antimyelin antibodies in multiple sclerosis (July 10 issue),1 Berger and colleagues restrict their report to IgM antibodies alone. Autoantibodies of the IgG class are, in general, more specific markers of autoimmune disease than those of the IgM class. Were IgG antibodies measured, and if so, how did they perform?

The authors also report that of the nine patients who were originally seronegative for antibodies and who subsequently had a relapse, eight were seropositive for antibodies at the time of relapse. Were antibodies measured sequentially in all the patients? If they . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.